Intech Investment Management LLC Raises Stock Position in DaVita Inc. $DVA

Intech Investment Management LLC grew its position in DaVita Inc. (NYSE:DVA) by 122.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,441 shares of the company’s stock after buying an additional 15,104 shares during the period. Intech Investment Management LLC’s holdings in DaVita were worth $3,646,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in DVA. KBC Group NV grew its position in DaVita by 38.7% in the second quarter. KBC Group NV now owns 374,749 shares of the company’s stock worth $53,383,000 after acquiring an additional 104,554 shares during the period. Nordea Investment Management AB lifted its stake in shares of DaVita by 1.8% in the 3rd quarter. Nordea Investment Management AB now owns 286,585 shares of the company’s stock valued at $37,864,000 after purchasing an additional 5,193 shares during the last quarter. Man Group plc lifted its stake in shares of DaVita by 1,608.6% in the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after purchasing an additional 269,081 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of DaVita by 132.1% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock worth $37,619,000 after purchasing an additional 150,318 shares during the period. Finally, Worldquant Millennium Advisors LLC increased its position in shares of DaVita by 49.1% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 257,845 shares of the company’s stock worth $36,730,000 after purchasing an additional 84,859 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

NYSE DVA opened at $156.28 on Monday. The firm has a market cap of $10.44 billion, a price-to-earnings ratio of 15.77, a PEG ratio of 0.55 and a beta of 0.93. The firm has a 50 day simple moving average of $124.18 and a 200-day simple moving average of $125.91. DaVita Inc. has a one year low of $101.00 and a one year high of $157.91.

DaVita (NYSE:DVA) last released its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The company had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same period in the prior year, the business earned $2.24 EPS. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Equities analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on DVA shares. Barclays upped their target price on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 3rd. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. UBS Group increased their price objective on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. TD Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. Finally, Truist Financial set a $158.00 price target on DaVita in a research note on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, DaVita presently has an average rating of “Hold” and an average target price of $155.80.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.